MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by LEO Pharma

< Previous 1 2 Next >
News headline image
LEO Pharma Submits New Drug Application for Enstilar® for Adults with Plaque Psoriasis in China
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Presents Late-Breaking Results from the Phase 2a Mechanism of Action Trial of Temtokibart and Dupilumab in Moderate-to-Severe Atopic Dermatitis at the 2024 EADV Annual Meeting
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Presents Late-Breaking Anzupgo® (delgocitinib) Cream Presentation at EADV 2024 Highlighting Results of Head-to-Head DELTA FORCE Trial in Chronic Hand Eczema (CHE)
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Unveils Most Extensive EADV Program To Date with 5 Late Breaking Abstracts and 23 Posters Sharing Clinical and Real-World Data
From LEO Pharma
Via Business Wire
News headline image
European Commission Approves LEO Pharma’s Anzupgo® (delgocitinib) Cream for Adults with Moderate to Severe Chronic Hand Eczema (CHE)
From LEO Pharma
Via Business Wire
News headline image
FDA Accepts LEO Pharma’s Filing of Delgocitinib Cream New Drug Application for the Treatment of Chronic Hand Eczema
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Presents Data from the Largest-Ever Multinational Real-World Studies of Chronic Hand Eczema (CHE) in Adults at the ESCD 2024 Congress
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Delivers 11% Revenue Growth (CER) in H1 and Upgrades Financial Outlook for the Year
From LEO Pharma
Via Business Wire
News headline image
Timber Pharmaceuticals, Inc., a LEO Pharma Company, Provides an Update on the Development Program for TMB-001 in Congenital Ichthyosis
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Receives Positive CHMP Opinion of Anzupgo® (delgocitinib cream) for the Treatment of Adults with Moderate to Severe Chronic Hand Eczema (CHE)
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Announces Publication of Chronic Hand Eczema Phase 3 Data in The Lancet
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Announces Topline Results of Phase 3 Trial in China for Enstilar® (LEO 90100) Demonstrating Superiority in Adult Chinese Subjects With Stable Plaque Psoriasis
From LEO Pharma
Via Business Wire
News headline image
Solid Start to the Year: LEO Pharma Delivers 13% Revenue Growth Driven by Strong Performance in Dermatology
From LEO Pharma
Via Business Wire
News headline image
Timber Pharmaceuticals, Inc., a LEO Pharma Company, Presents Late-Breaking Preliminary Results of TMB-001 in Moderate-to-Severe Congenital Ichthyosis (CI) at the 2024 AAD Annual Meeting
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma to Maintain Leadership Role at AAD in 2024 with New Late-Breaking Data Spanning Multiple Therapeutic Areas
From LEO Pharma
Via Business Wire
News headline image
Annual Report 2023: LEO Pharma Delivers 10% Revenue Growth and Returns to Positive EBITDA
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Announces Positive Phase 3 Head-to-head Data Results from DELTA FORCE Trial Comparing Delgocitinib Cream With Alitretinoin Capsules in Adults With Severe Chronic Hand Eczema (CHE)
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Finalizes Acquisition of Key Assets From Timber Pharmaceuticals
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Inc. Announces U.S. FDA approval of Adbry® (tralokinumab-ldrm) for the Treatment of Moderate-to-severe Atopic Dermatitis in Pediatric Patients Aged 12-17 Years
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Announces Positive Outcome of DELTA 3 Open-Label Extension Trial of Delgocitinib Cream in the Treatment of Adults With Moderate to Severe Chronic Hand Eczema (CHE)
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Presents Phase 3 Results of Delgocitinib Cream for Adults with Moderate to Severe Chronic Hand Eczema (CHE) at EADV 2023
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Presents New Long-Term Data on Use of Adtralza® (tralokinumab) to Treat Moderate-to-Severe Atopic Dermatitis (AD)
From LEO Pharma
Via Business Wire
News headline image
Temtokibart achieves First Subject First Treatment (FSFT) milestone in Phase 2b trial
From LEO Pharma
Via Business Wire
News headline image
Globally Known Professor and Dermatologist Joins LEO Pharma
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma delivers solid first half-year results and strengthens its capital structure
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma announces changes to its Global Leadership Team
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Signs Agreement to Acquire Timber Pharmaceuticals
From LEO Pharma
Via Business Wire
News headline image
EMA Accepts LEO Pharma’s Marketing Authorization Application (MAA) for Delgocitinib Cream in Chronic Hand Eczema (CHE)
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Presents Late-Breaking Positive Phase 2a Efficacy and Safety Results of LEO 138559 in Moderate-to-Severe Atopic Dermatitis at the 2023 AAD Annual Meeting
From LEO Pharma
Via Business Wire
News headline image
LEO Pharma Presents Late-Breaking Positive Phase 3 Results of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (CHE) at AAD 2023
From LEO Pharma
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story